PROSTATE CANCER

Updated January 2016 by Dr. Kristy Wasson (PGY-5 Medical Oncology Resident, University of Toronto)
and August 2017 by Dr. Jenny Ko (Staff Oncologist, Abbotsford Cancer Centre, BCCA)

Reviewed by Dr. Nimira Alimohammed (Staff Oncologist, University of Calgary) and Dr. Scott Berry
(Staff Oncologist, University of Toronto) in 2016

A) PUBLIC HEALTH
EPIDEMIOLOGY
- Incidence: 99 per 100,000. Most common cancer among men (excluding non-melanoma skin
cancers), accounts for 24% of all new male cancer cases in Canada.
- Mortality: 3rd leading cause of cancer death in men in Canada (17 deaths per 100,000).

RISK FACTORS
- Environmental/Chemical/Infections: consumption of a diet rich in red meat and saturated
fat appears to increase risk, particularly of aggressive disease.
- Genetic: increasing age is the most important risk factor, higher incidence in North American
blacks compared with other ethnic groups and often has a more aggressive course, risk
increased twofold in men with one or more affected first-degree relatives, BRCA1 and BRCA2
carriers have an increased risk (1.8- and 4.7-fold).

PREVENTION & SCREENING

- Prevention: Finasteride and Dutasteride (5-AR inhibitors) have been shown to decrease the risk
of prostate cancer, but with with an elevated rate of high-grade prostate cancers and no change
in overall survival.
- Screening: Serum PSA screening is of unknown value as a population screening test. RCTs
have shown a small reduction in prostate-cancer mortality, but harms associated with
screening, including over-diagnosis and treatment are common.
- Evidence for: The European Randomized Study of Screening for Prostate Cancer (ERSPC)
i
Study found a 20% reduction in prostate cancer death screening men aged 55-69, with an
absolute risk reduction 0.71 deaths per 1000 men. To prevent 1 death: 1410 men need to
be screened for 9 years and 48 additional cases diagnosed and treated.
ii
- Evidence against: The Prostate, Lung, Colorectal, Ovarian (PLCO) trial followed 77,000 men
between 55 and 74 for 13 years and found the death rate from prostate cancer was low and did
not differ between the screened and control (unscreened) groups.
- Cancer Care Ontario does not support an organized, population-based screening program
for prostate cancer.
- BCCA, Alberta Cancer Guidelines recommend that fit men between the ages of 50 and 75 years
with at least 10 years life expectancy should be made aware of the availability of PSA as a
detection test for prostate cancer, as well as the potential benefits and risks of early detection,
so they can make an informed decision as to whether to have the test performed.
- Canadian Task Force recommends against PSA screening for prostate cancer (CMAJ 2014).
Ref. 1) Schroder F et al. N Engl J Med. 2009 Mar 26;360(13):1320.
2) Andriole GL et al. N Engl J Med. 2009 Mar 26;360(13):1310.

B) PRESENTATION & DIAGNOSIS

SYMPTOMS & SIGNS

- Localized disease - vast majority - present with an abnormal digital rectal examination (DRE) or
PSA screening
- Locally advanced disease - lower urinary symptoms: hesitancy, weak stream,
frequency, nocturia, incomplete bladder emptying
- Metastatic disease - constitutional symptoms, bony pain
INVESTIGATIONS
- History and Physical including DRE
- Laboratory: PSA, CBC, Calcium profile, Creatinine, ALP and LFTs
- Transrectal biopsy - typically 10-12 core
- Radiology: CT chest/abdo/pelvis and bone scan in intermediate/high risk
- If symptoms or signs of cord compression: MRI whole spine

PATHOLOGY & MOLECULAR BIOLOGY

- Most common histology is adenocarcinoma (>95%)
- Gleason Score = sum of two most common tumour patterns, most common stated first
- Other: sarcomatoid, endometrioid
- Transitional cell carcinoma should be treated as a urothelial cancer
- Sarcomas are rare and should be treated per sarcoma guidelines

STAGING
- TNM
o T1: clinically inapparent tumour not palpable or visible by imaging
▪ T1a: Tumor incidental histologic finding in 5% or less of tissue resected
▪ T1b: Tumor incidental histologic finding in more than 5% of tissue resected
▪ T1c: Tumor identified by needle biopsy (eg, because of elevated PSA)
o T2: tumour confined within the prostate
▪ T2a: tumour involves one lobe
▪ T2b: tumour involves both lobes
o T3: tumour extends through the prostatic capsule
▪ T3a: extracapsular extension (unilateral or bilateral)
▪ T3b: tumour invades seminal vesicle(s)
o T4: tumour is fixed or invades adjacent structures other than seminal vesicles: bladder
neck, external sphincter, rectum, levator muscles, and/or pelvic wall
o N1: regional lymph node metastasis (pelvic nodes below the bifurcation of the
common iliac arteries)
o M1a: non-regional lymph node(s), M1b: bone(s), M1c: other site(s) with or without bone
disease
o Stage 1: T1aN0M0 + Gleason score 2-4
o Stage 2A: T1aN0M0 + Gleason score 5-6, T1b-T1cN0M0 any Gleason o
Stage 2B: T2N0M0 any Gleason
o Stage 3A: T3N0M0 any Gleason
o Stage 4: T4N0M0 any Gleason, anyTN1M0 any Gleason, anyT anyN M1 any Gleason
- Low Risk: PSA ≤10 ng/mL + Gleason ≤ 6 + Stage T1/T2a
- Intermediate Risk: neither low or high risk, any of: PSA 10-20, Gleason 7, Stage 2B
- High Risk : any of PSA > 20 ng/mL or Gleason ≥ 8 or Stage T3a or worse

C) TREATMENT
I) LOCALIZED Prostate Cancer
- Bottom Line General Approach:
o Low Risk options: Active Surveillance (CCO & ASCO guideline preference; see below),
Prostatectomy, EBRT, brachytherapy
o Intermediate Risk options: Prostatectomy, EBRT + brachytherapy boost or
brachytherapy alone. EBRT + short-term Androgen Deprivation Therapy (ADT; 4-6
months) option for non-brachy/non-surgical patients
o High Risk options: EBRT + brachytherapy boost + 18-36 months ADT or Prostatectomy.
EBRT + long-term ADT option for non-brachy/non-surgical patients
o Prostatectomy and RT have not been compared head to head
o 3 RCTs show brachy boost > EBRT for intermediate and high risk patients (+/- ADT)
 o Adjuvant ADT following EBRT - multiple randomized trials have demonstrated
improvement in cancer-specific and overall survival with adjuvant ADT following EBRT in
high-risk disease (RTOG 86-10, EORTC 22863, RTOG 85-31). 3 years was found to be
superior to 6 months of ADT but 18 months = 36 months (Quebec PCS3 study). Adjuvant
ADT in intermediate risk is less clear for brachytherapy patients but data supports 4-6mo
ADT with EBRT. The RTOG 0815 trial has recently closed in which adjuvant 6mo ADT
is being investigated with modern high-dose radiation (data won’t be avail until at least
2021).
o Neoadjuvant ADT with Radical Prostatectomy has been explored in over 20 trials and
although several studies demonstrated a reduction in the rate of positive surgical margins,
this did not translate to improvements in biochemical progression free survival
or overall survival and is not currently recommended.
o Adjuvant or Neoadjuvant Chemotherapy - Clinical trials currently ongoing:
▪ RTOG 0521 EBRT (72-75 Gy) + ADT x 2 years +/- adjuvant Docetaxel -
presented at ASCO 2015. For high-risk, localized PCa, adjuvant
Docetaxel improved OS from 89% to 93% at 4 years.
▪ CALGB 90203 - Phase III trial of neoadjuvant docetaxel plus ADT followed by
radical prostatectomy versus immediate radical prostatectomy
o Adjuvant Radiation: patients with adverse histologic features (extracapsular extension,
seminal vesicle involvement, positive margins, or lymph node involvement) should be
referred to radiation oncology for consideration of adjuvant RT (CCO, ASCO & AUA
guidelines)
o Salvage RT: persistent elevation or rising PSA after surgery should be referred to radiation
oncology for consideration of adjuvant RT (> 0.2 ng/mL) (CCO, ASCO & AUA
guidelines). 2 years of bicalutamide 150mg found to improve OS and MFS in salvage
radiotherapy setting (RTOG 9601)
o If age or comorbidity preclude definitive therapy in men with intermediate or high-risk
prostate cancer, systemic therapy with ADT may be useful as a palliative approach,
although this has been associated with shorter overall survival than definitive therapy.
- Active Surveillance: observation rather than immediate therapy in low-risk patients as a
means of avoiding over-treatment. Toronto prospective cohort protocol: serum PSA at three
month intervals, with a PSA doubling time of three years or less as a criterion for active
intervention; repeat prostate biopsy is performed at one year then repeated every four to five
years to look for evidence of biologic progression to Gleason 4+3 or higher.
- Prognosis: low risk disease: 10-year prostate cancer survival rates >99%; intermediate risk
95-98%; high risk localized disease 80-90%.
- Surveillance after definitive treatment: serum PSA every 3-6 months for the first 2 years then
q6mo thereafter. Biopsies done at 1y then q3y. Role of MR-guided biopsies has been
investigated (ASIST - results expected late 2016)

II) Hormone-Sensitive Metastatic Prostate Cancer

I) Bottom Line General Approach: Initial options include Androgen Deprivation Therapy (ADT) or
combined Chemohormonal Therapy (ADT + 6 cycles of Docetaxel)
I) ADT = lowering serum testosterone to castrate levels (<1.7 nmol/L or <50 ng/dL). Surgical
orchiectomy (castration) and Medical orchiectomy with GnRH agonist or GnRH antagonist
are equally effective. Anti-androgens (ie Bicalutamide) are often combined with GnRH
agonists at the start of therapy for 2-4 weeks to prevent symptom flare due to transient
increase in testosterone. Several meta -analyses have shown small improvements in OS
with complete androgen blockade (GnRHa + anti-androgen) but with increased toxicity.
II) Early vs Delayed ADT - 2007 meta-analysis showing no significant OS benefit to early ADT,
however, heterogeneous population and no prognostic factors incorporated into studies.
III) Intermittent vs Continuous ADT - controversial. INT-0162 Phase III trial showing intermittent
ADT is NOT non-inferior to ADT with respect to OS.
IV) Side effects of ADT: vasomotor symptoms, decreased libido, decreased muscle mass,
decreased energy, metabolic syndrome, osteopenic effects
V) Calcium and Vitamin D should be given to all men on ADT
 VI) Biochemical progression on standard ADT is treated with secondary hormonal manipulations:
addition of bicalutamide and bicalutamide withdrawal. Steroidal anti -androgens (ie
ketoconazole) are not as commonly used since the development of abiraterone and
enzalutamide.
VII) 3 Phase III RCT (CHAARTED, Stampede (ASCO 2015), GETUG-AFU 15) have evaluated
early Docetaxel in combination with ADT in metastatic castrate sensitive prostate cancer.
CHAARTED and Stampede showed improved PFS and OS with early Docetaxel + ADT
compared to ADT alone (*GETUG-AFU 15 did not show a statistically significant increase
in OS). Median OS in the low-volume disease subgroup has not been reached and
additional follow-up is required. Stampede has not yet been published.
VIII) 2 Phase III RTCs (LATITUDE, STAMPEDE) have been published to show OS benefit of
abiraterone/prednisone added to ADT within 3 months of initiation of ADT (see below for
details). No data on docetaxel vs. abiraterone/prednisone in this setting.

II) Prognosis: 42-44 months with ADT alone vs 57 months with combined chemohormonal therapy
– shorter with high volume disease, see CHAARTED

III) Important Phase III clinical trials:

CHAARTED: Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

Reference: Sweeney et al. NEJM 2015;373:737.

Regimen Androgen Deprivation Therapy (ADT) with LHRHa alone vs ADT +

Docetaxel 75 mg/m2 on day 1 every 3 weeks x 6 cycles
Mechanism of Action Docetaxel: inhibits polymerization of tubulin therefore inhibiting DNA,
of Experimental RNA and protein synthesis.
Drug

Primary Endpoint OS
Inclusion/Exclusion Pathological diagnosis of prostate cancer or clinical scenario
Criteria consistent
Radiographic evidence of metastatic disease
ECOG 0-2
Prior adjuvant ADT allowed if ≤ 24 mos and completed ≥ 12 mos prior
ADT commenced within 120 days of randomization

Size (N) 790

Results Survival: mOS 57.6 mos vs 44.0 mos, HR 0.61
Subgroup with high volume disease: mOS 49.2 mos vs 32.2 mos
HR 0.60
Subgroup with high volume disease: mOS not reached in low
volume group
Decrease in PSA to ≤ 0.2ng/ml at 12 mos: 27.7% vs 16.8%
Time to development of castration-resistant PCa: 20.2 mos vs
11.7 mos
Toxicity Grade 3 or 4 neutropenia 32%, febrile neutropenia 3%
Common toxicities include fatigue, n/v/d, neuropathy (30%), edema
Conclusion Six cycles of docetaxel at the beginning of ADT for metastatic
prostate cancer resulted in significantly longer overall survival than
that with ADT alone.
Other Comments high volume disease defined as visceral mets or ≥ 4 bony mets with ≥
1 outside axial skeleton
 GETUG-AFU 15: Androgen-deprivation therapy alone or with docetaxel in non-castrate
metastatic prostate cancer: a randomized, open-label Phase 3 trial.
Reference: Gravis et al. Lancet Oncol 2013;14:149.

Regimen Androgen Deprivation Therapy (ADT) with LHRHa alone or

orchiectomy vs ADT + Docetaxel 75 mg/m2 on day 1 every 3 weeks
x 9 cycles
Mechanism of Action Docetaxel: inhibits polymerization of tubulin therefore inhibiting DNA,
of Experimental RNA and protein synthesis.
Drug

Primary Endpoint OS
Inclusion/Exclusion Histologically confirmed adenocarcinoma of the prostate
Criteria Radiographic evidence of metastatic disease
Karnofsky PS ≥70%
ADT commenced within 2 months of enrolment
Prior neoadjuvant or adjuvant therapy completed ≥ 12 months prior

Size (N) 385

Results Survival: mOS 62 mos vs 49 mos, HR 0.88 (0.68-1.14) NS
biochemical PFS: 22.9 mos vs 12.9 mos, HR 0.67
Median time to subsequent treatment: 20 mos vs 15.4 mos
Fall in PSA ≥50% at 6 months: 94% vs 85%

Toxicity Neutropenia 21%, febrile neutropenia 3%, abnormal LFTs 2%

Conclusion Docetaxel should not be used as part of first-line treatment for patients
with non-castrate metastatic prostate cancer.
Other Comments

Addition of docetaxel, zoledronic acid, or both to fi rst-line long-term hormone therapy in

prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage,
platform randomised controlled trial
James Lancet Volume 387, No. 10024, p1163–1177, 19 March 2016

Regimen • Standard of care was hormone therapy for at least 2 years;

radiotherapy was encouraged for men with N0M0 disease to
November, 2011, then mandated; radiotherapy was optional for men
with node-positive non-metastatic (N+M0) disease. Stratified
randomisation (via minimisation) allocated men 2:1:1:1 to standard
of care only (SOC-only; control), standard of care plus zoledronic
acid (SOC + ZA), standard of care plus docetaxel (SOC + Doc), or
standard of care with both zoledronic acid and docetaxel (SOC + ZA
+ Doc). Zoledronic acid (4 mg) was given for six 3-weekly cycles,
then 4-weekly until 2 years, and docetaxel (75 mg/m2) for six 3-
weekly cycles with prednisolone 10 mg daily.
Primary Endpoint • OS
Inclusion/Exclusion • men with high-risk, locally advanced, metastatic or recurrent prostate
Criteria cancer who are starting first-line long-term hormone therapy
Size (N) • N=2962
Results • Median age was 65 years (IQR 60–71).
• 1817 (61%) men had M+ disease, 448 (15%) had N+/X M0, and 697
(24%) had N0M0.
 • 165 (6%) men were previously treated with local therapy, and
median prostate-specific antigen was 65 ng/mL (IQR 23–184).
Median follow-up was 43 months (IQR 30–60).
• There were 415 deaths in the control group (347 [84%] prostate
cancer). Median overall survival was 71 months (IQR 32 to not
reached) for SOC-only, not reached (32 to not reached) for SOC
+ ZA (HR 0·94, 95% CI 0·79–1·11; p=0·450), 81 months (41 to not
reached) for SOC + Doc (0·78, 0·66–0·93; p=0·006), and 76
months (39 to not reached) for SOC + ZA + Doc (0·82, 0·69–0·97;
p=0·022). There was no evidence of heterogeneity in treatment
effect (for any of the treatments) across prespecified subsets. Grade
3–5 adverse events were reported for 399 (32%) patients receiving
SOC, 197 (32%) receiving SOC + ZA, 288 (52%) receiving SOC +
Doc, and 269 (52%) receiving SOC + ZA + Doc.
• Subgroup analysis, OS
- M0 HR 0.95 (crosses 1)
- M1 HR 0.76 (significant)
Conclusion • Zoledronic acid showed no evidence of survival improvement and
should not be part of standard of care for this population. Docetaxel
chemotherapy, given at the time of long-term hormone therapy
initiation, showed evidence of improved survival accompanied by an
increase in adverse events. Docetaxel treatment should become part
of standard of care for adequately fit men commencing long-term
hormone therapy.

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

(LATITUDE)
Fizazi N Engl J Med 2017; 377:352-360

Regimen • Androgen-deprivation therapy plus abiraterone acetate (1000 mg

daily, given once daily as four 250-mg tablets) plus prednisone (5
mg daily) (the abiraterone group) or androgen-deprivation therapy
plus dual placebos (the placebo group).
Primary Endpoint • OS
• Radiographic PFS
Inclusion/Exclusion • Patients with newly diagnosed, metastatic, castration-sensitive
Criteria prostate cancer starting ADT <3m
• All the patients had high-risk, metastatic, castration-sensitive
prostate cancer, as documented by a positive bone scan or
metastatic lesions at the time of diagnosis on computed tomography
(CT) or magnetic resonance imaging (MRI), according to Response
Evaluation Criteria in Solid Tumors (RECIST), version 1.1.
• In addition, the patients were required to have at least two of the
three following high-risk factors associated with poor prognosis: a
Gleason score of 8 or more (on a scale of 2 to 10, with higher
scores indicating more aggressive disease), at least three bone
lesions, and the presence of measurable visceral metastasis.
Size (N) • N=1199
Results • After a median follow-up of 30.4 months at a planned interim
analysis (after 406 patients had died), the median overall survival
was significantly longer in the abiraterone group than in the placebo
group (not reached vs. 34.7 months) (hazard ratio for death, 0.62;
95% confidence interval [CI], 0.51 to 0.76; P<0.001).
• The median length of radiographic progression-free survival was
33.0 months in the abiraterone group and 14.8 months in the
placebo group (hazard ratio for disease progression or death, 0.47;
95% CI, 0.39 to 0.55; P<0.001).
• Significantly better outcomes in all secondary end points were
 observed in the abiraterone group, including the time until pain
progression, next subsequent therapy for prostate cancer, initiation
of chemotherapy, and prostate-specific antigen progression
(P<0.001 for all comparisons), along with next symptomatic skeletal
events (P=0.009).
• These findings led to the unanimous recommendation by the
independent data and safety monitoring committee that the trial be
unblinded and crossover be allowed for patients in the placebo
group to receive abiraterone.
Toxicity • Similar to known S/E of abiraterone/prednisone
• Rates of grade 3 hypertension and hypokalemia were higher in the
abiraterone group.
Conclusion • The addition of abiraterone acetate and prednisone to androgen-
deprivation therapy significantly increased overall survival and
radiographic progression-free survival in men with newly diagnosed,
metastatic, castration-sensitive prostate cancer.

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
(STAMPEDE)
James N Engl J Med 2017; 377:338-351

Regimen • ADT alone or ADT plus abiraterone acetate (1000 mg daily) and
prednisolone (5 mg daily) (combination therapy)
• Local radiotherapy was mandated for patients with node-negative,
nonmetastatic disease and encouraged for those with positive
nodes. For patients with nonmetastatic disease with no radiotherapy
planned and for patients with metastatic disease, treatment
continued until radiologic, clinical, or prostate-specific antigen (PSA)
progression; otherwise, treatment was to continue for 2 years or until
any type of progression, whichever came first.
Primary Endpoint • OS
Inclusion/Exclusion • Eligible patients had prostate cancer that was newly diagnosed and
Criteria metastatic, node-positive, or high-risk locally advanced (with at
least two of following: a tumor stage of T3 or T4, a Gleason score of
8 to 10, and a PSA level ≥40 ng per milliliter) or disease that was
previously treated with radical surgery or radiotherapy and was now
relapsing with high-risk features (in men no longer receiving
therapy, a PSA level >4 ng per milliliter with a doubling time of <6
months, a PSA level >20 ng per milliliter, nodal or metastatic
relapse, or <12 months of total ADT with an interval of >12 months
without treatment).
• Patients were intended for treatment with long-term ADT that started
no longer than 12 weeks before randomization. There were no age
restrictions. Patients with clinically significant cardiovascular disease
(e.g., severe angina, recent myocardial infarction, or a history of
cardiac failure) were excluded.
Size (N) • N=1917
Results • There were 248 treatment-failure events in the combination group as
compared with 535 in the ADT-alone group (hazard ratio, 0.29; 95%
CI, 0.25 to 0.34; P<0.001); the hazard ratio was 0.21 in patients with
nonmetastatic disease and 0.31 in those with metastatic disease.
• For OS, M0 – HR 0.75, crosses 1; M1 -HR 0.61, significant
• mFU 40m
• There were 184 deaths in the combination group as compared with
262 in the ADT-alone group (hazard ratio, 0.63; 95% confidence
interval [CI], 0.52 to 0.76; P<0.001); the hazard ratio was 0.75 in
patients with nonmetastatic disease and 0.61 in those with
metastatic disease.
 • Restricted mean failure-free survival time: 43.9 months in the
combination group and 30.0 months in the ADT-alone group in the
first 54 months after randomization, a difference of 13.9 months
(95% CI, 12.3 to 15.4). The effect of abiraterone on failure-free
survival was noted in all subgroups
• The 3-year progression-free survival was 80% in the combination
group and 62% in the ADT-alone group (hazard ratio for clinical or
radiologic progression or death from prostate cancer, 0.40; 95% CI,
0.34 to 0.47; P<0.001)
• FFS M0 – HR 0.21; M1 – HR 0.31 Both significant
Toxicity • Grade 3 to 5 adverse events occurred in 47% of the patients in the
combination group (with nine grade 5 events) and in 33% of the
patients in the ADT-alone group (with three grade 5 events).
Conclusion • Among men with locally advanced or metastatic prostate cancer,
ADT plus abiraterone and prednisolone was associated with
significantly higher rates of overall and failure-free survival than ADT
alone.
III) Castrate-Refractory Metastatic Prostate Cancer (mCRPC)
I) Bottom Line General Approach:
I) Treatment options for mCRPC include taxane chemotherapy (Docetaxel, Cabazitaxel), anti-
androgens Abiraterone Acetate and Enzalutamide and Radium-223. 1st line options include
Docetaxel, Abiraterone, Enzalutamide and Radium-223. Post-Docetaxel options include
Abirterone, Enzalutamide, Radium-223 and Cabazitaxel.
II) Palliative radiotherapy is also frequently used for cancer-related pain from bone metastases
III) New treatment options were developed in parallel and the optimal sequencing of treatments is
unknown but of increasing importance. Currently, decisions are based on patient factors (co-
morbidities, performance status, cancer-related symptoms, contraindications) and disease
factors (site of disease: lymph node or bone only sites vs visceral metastases, duration of
response to ADT and aggressiveness: rate of progression/de novo metastatic
disease/high Gleason score)
IV) Abiraterone and Enzalutamide show decreased rates of PSA response when used
subsequent to the other indicative of cross resistance.
V) Use of bisphosphates (Zoledronic Acid) or Denosumab decreases skeletal related events but
does not improve OS or QOL.
1) Saad et al. J Natl Cancer Inst 2004; 96:879-882.
2) Fizazi et al. Lancet 2011; 377:813-822.
 II) Prognosis: 35 months with most recent trials vs 16 months without treatment in
TAX327 (Mitoxantrone does not improve OS)
III) Important Phase III Clinical Trials

TAX 327: Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced
Prostate Cancer.
Reference: Tannock IF et al. NEJM 2004;351:1502.

Regimen Up to 10 cycles of Docetaxel (75 mg/m2 on day 1 every 3 weeks) OR

up to 5 cycles of weekly Docetaxel (30 mg/m2 on day 1, 8, 15, 22, 29
of a 6 week cycle) plus plus prednisone 5mg BID vs. Mitoxantrone
(12 mg/m2 on day 1 every 3 weeks) plus prednisone 5mg BID
Mechanism of Action Docetaxel: inhibits polymerization of tubulin therefore inhibiting DNA,
of Experimental RNA and protein synthesis.
Drug

Primary Endpoint OS
Inclusion/Exclusion No prior cytotoxic treatment
Criteria Karnofsky PS >/= 60%
Disease progression on hormonal treatment

Size (N) 1006

Results Survival: mOS 18.9 mos in q3 weekly Docetaxel vs 16.5 mos in
Mitoxantrone, no significant improvement with weekly Docetaxel
PSA Response: 45%, 48% Docetaxel vs 32% Mitoxantrone (p<0.01)
QOL: Improved QOL with both Docetaxel groups vs Mitoxantrone
Pain: decreased with q3 weekly Docetaxel
Toxicity Grade 3 or 4 neutropenia 32%, febrile neutropenia 3%
Common toxicities include fatigue, n/v/d, neuropathy (30%), edema
Conclusion Docetaxel q3 weeks (but not weekly Docetaxel) plus prednisone led
to superior survival and improved rates of response in terms of pain,
serum PSA level, and quality of life, as compared with mitoxantrone
plus prednisone. This is the first study to show a survival benefit in
mCRPC.

Other Comments (e.g. any criticisms about the study)

Post-Docetaxel

AFFIRM: Increased Survival with Enzalutamide in Prostate Cancer after

Chemotherapy. Reference: Scher HI et al. NEJM 2012;367:1187.

Regimen Enzalutamide (MDV3100) 160mg PO daily vs. placebo

Mechanism of Action Enzalutamide: androgen receptor antagonist, inhibits translocation of
of Experimental AR into cell nucleus and inhibits AR binding to DNA
Drug

Primary Endpoint OS
Inclusion/Exclusion Castrate levels of testosterone (<50 ng/ deciliter [1.7 nmol/ liter])
Criteria Previous treatment with Docetaxel
ECOG 0-2
Disease progression (radiographic or rising PSA on 3 occasions)

Size (N) 1199

Results Survival: mOS 18.4 mos vs 13.6 mos, HR 0.63
PSA Response: increased with Enzalutamide (54% vs 2%)
ORR: increased with Enzalutamide (29% vs 4%)
QOL: increased with Enzalutamide (43% vs 18%)
time to first skeletal event: increased with Enzalutamide (16.7 mos
vs 13.3 mos)
time to PSA progression: increased with Enzalutamide 8.3 mos vs
3.0 mos
PFS: increased with Enzalutamide 8.3 mos vs 2.9 mos
Toxicity Seizure 0.6%
Common: fatigue, diarrhea, hot flashes, headache, MSK pain
Conclusion Enzalutamide significantly prolonged survival in men with metastatic
castration resistant prostate cancer after chemotherapy.

Other Comments Drug interactions

 COU-AA-301: Abiraterone and Increased Survival in Metastatic Prostate Cancer.
Reference: de Bono et al. NEJM 2011;364:1995.

Regimen Abiraterone 1000mg PO daily + prednisone 5mg BID vs. placebo +

prednisone 5mg BID
Mechanism of Action Abiraterone: irreversible and specific inhibitor of CYP17 (inhibits
of Experimental androgen synthesis)
Drug

Primary Endpoint OS
Inclusion/Exclusion Castrate levels of testosterone (<50 ng/ deciliter [2 nmol/ liter])
Criteria Previous treatment with Docetaxel
ECOG 0-2
Disease progression (radiographic or rising PSA on 2 occasions)

Size (N) 1195

Results Survival: mOS 14.8 mos vs 10.9 mos, HR 0.65
PSA Response: increased with Abiraterone (29% vs 6%)
ORR: increased with Abiraterone (14% vs 3%)
Rate of pain palliation: increased with Abiraterone (44% vs 27%)
Time to first skeletal event in 25%: increased with Abiraterone (9.9
vs 4.9 mos)
Time to PSA progression: 10.2 mos vs 6.6 mos
PFS: 5.6 mos vs 3.6 mos
Toxicity Common: fatigue, back pain, nausea, constipation, bone pain -
similar frequency as placebo
Hypokalemia (17%), fluid retention (31%), hypertension (10%),
cardiac events (13%), AST/ALT elevation (10%, same as placebo)
Conclusion Abiraterone abiraterone acetate prolonged overall survival among
patients with metastatic castration-resistant prostate cancer who
previously received chemotherapy.

Other Comments (e.g. any criticisms about the study)

TROPIC: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant
prostate cancer progressing after docetaxel treatment: a randomised open label trial.
Reference: de Bono et al. Lancet 2010;376:1147.

Regimen Up to 10 cycles of Cabazitaxel (25 mg/m2 q21 days) + prednisone

10mg daily vs. Mitoxantrone (12mg/m2 q 21days) + prednisone 10mg
daily. Prophylactic GCSF allowed after 1st occurrence of febrile
neutropenia or neutropenia greater than 7 days
Mechanism of Action Cabazitaxel: inhibits polymerization of tubulin therefore inhibiting
of Experimental DNA, RNA and protein synthesis.
Drug

Primary Endpoint OS
Inclusion/Exclusion Previous treatment with Docetaxel
Criteria Disease progression (radiographic or rising PSA on 2 occasions)
ECOG 0-2
Ongoing castration by orchiectomy or LHRHa
>/= Grade 2 peripheral neuropathy excluded

Size (N) 755

Results Survival: mOS 15.1 mos vs 12.7 mos, HR 0.7
PSA Response: increased with Cabazitaxel (39.2% vs 17.8%)
ORR: increased with Cabazitaxel (14% vs 4%)
Time to PSA progression: 8.8 mos vs 5.4 mos
mPFS: 2.8 mos vs 1.4 mos
Rate of pain palliation: no difference
Time to pain progression: no difference
Toxicity Grade 3 or 4 neutropenia 82%, febrile neutropenia 8%, diarrhea 6%
Common toxicities include haematologic, diarrhea, fatigue, n/v
Conclusion Cabazitaxel plus prednisone improves overall survival in patients with
metastatic castration-resistant prostate cancer whose disease has
progressed during or after docetaxel-based therapy.

Other Comments (e.g. any criticisms about the study)

 ALSYMPCA: Alpha emitter Radium-223 and Survival in Metastatic Prostate
Cancer Reference: Parker et al. NEJM 2013;369:213.

Regimen Up to 6 injections of Radium-223 50kBq/kg on Day 1 every 4 weeks

vs. Placebo
Mechanism of Action Radium-223: targeted alpha emitter that selectively binds to areas of
of Experimental increased bone turnover in bone metastases and induces double-
Drug stranded DNA breaks

Primary Endpoint OS
Inclusion/Exclusion Castrate levels of testosterone (<50 ng/ deciliter [1.7 nmol/ liter])
Criteria 2 or more bone metastases
No visceral metastases, lymph node mets <3cm
Symptomatic disease: regular use of analgesics or radiation for
cancer-related bone pain in previous 12 weeks
Previous treatment with Docetaxel, not a candidate for Docetaxel or
declined Docetaxel**
PSA of at least 5ng/ml and with 2 consecutive increases
ECOG 0-2

Size (N) 921

Results Survival: mOS 14.9 mos vs 11.3 mos, HR 0.7
Time to first skeletal event: 15.6 mos vs 9.8 mos, HR 0.66
Time to an increase in ALP: 7.4 mos vs 3.8 mos
Time to an increase in PSA: 3.6 vs 3.4 mos
PSA response: 16% vs 6%
≥30% reduction in ALP: 47% vs 3%
Normalization of ALP: 34% vs 1%
Improved QOL: 25% vs 16%
Toxicity The number of patients experiencing an adverse event was
consistently lower in the Radium-223 group than in the placebo group
for all adverse events
No clinically meaningful differences in the frequency of hematologic
adverse events were observed between groups.
Conclusion Radium-223 significantly prolonged overall survival in patients who
had castration-resistant prostate cancer previously treated with (or
ineligible for) Docetaxel and symptomatic bone metastases

Other Comments **only ~60% were post-Docetaxel, others were “non”-Docetaxel

Pre-Docetaxel

COU-AA-302: Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy.

Reference: Ryan et al. NEJM 2013;368:138 and Ryan et al. Lancet Oncol 2015;16:152.

Regimen Abiraterone 1000mg PO daily + prednisone 5mg BID vs. placebo +

prednisone 5mg BID
Mechanism of Action Abiraterone: irreversible and specific inhibitor of CYP17 (inhibits
of Experimental androgen synthesis)
Drug
Primary Endpoint OS*
Radiographic PFS *co-primary endpoints
Inclusion/Exclusion Castrate levels of testosterone (<50 ng/ deciliter [1.7 nmol/ liter])
Criteria Disease progression (radiographic or rising PSA on 2 occasions)
Chemotherapy-naive
ECOG 0-1
No symptoms or mild symptoms on BPI-SF
Pts with visceral metastases excluded
Pts treated with ketoconazole > 7 days were excluded

Size (N) 1088

Results mPFS: 16.5 vs 8.3 mos, HR 0.53
Survival: mOS 34.7 mos vs 30.3 mos, HR 0.81
PSA Response: 62% va 24%
ORR: 36% vs 16%
Time to initiation of cytoxic chemotherapy: 25.2 mos vs 16.8 mos
Time to opiate use for cancer-related pain: 33.4 mos vs 23.4 mos
Time to decline in ECOG PS: 12.3 mos vs 10.9 mos
Time to PSA progression: 11.1 mos vs 5.6 mos
Toxicity Fatigue, arthralgia, peripheral edema - more common than placebo
Hypokalemia (17%), fluid retention (28%), hypertension (22%),
cardiac events (19%), AST/ALT elevation (8%)
Conclusion Abiraterone improved radiographic PFS, overall survival, and delayed
clinical decline, time to initiation of chemotherapy and time to opiate
use in patients with metastatic castration-resistant prostate cancer.

Other Comments (e.g. any criticisms about the study)

 PREVAIL: Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Reference: Beer et al. NEJM 2014;371:424.

Regimen Enzalutamide (MDV3100) 160mg PO daily vs. placebo

Mechanism of Action Enzalutamide: androgen receptor antagonist, inhibits translocation of
of Experimental AR into cell nucleus and inhibits AR binding to DNA
Drug
Primary Endpoint OS*
Radiographic PFS* co-primary endpoints
Inclusion/Exclusion Castrate levels of testosterone (<50 ng/ deciliter [1.7 nmol/ liter])
Criteria Disease progression (radiographic or rising PSA on 2 occasions)
No prior cytotoxic chemotherapy, ketoconazole or abiraterone
ECOG 0-1
No symptoms or mild symptoms on BPI-SF
Pts with visceral metastases eligible
History of seizure or condition predisposing to seizure excluded

Size (N) 1717

Results Survival: 12-month OS 72% vs 63%, HR 0.71
PFS: 12-month Radiographic PFS 65% vs 14%, HR 0.19
PSA Response: 78% vs 3%
ORR: 59% vs 5%
Time to initiation of cytoxic chemotherapy: 28 mos vs 10.8 mos
Time to PSA progression: 11.2 mos vs 2.8 mos
Time to first skeletal-related event: 31.1 most vs 31.3 mos
Time to decline in FACT-P global score: 11.3 mos vs 5.6 mos

Toxicity Common: fatigue, hypertension

Conclusion Enzalutamide significantly decreased the risk of radiographic
progression and death and delayed the initiation of chemotherapy in
men with metastatic prostate cancer.

Other Comments
Other References
1) Canadian Cancer Statistics 2015
2) UpToDate
3) Alberta Cancer Guidelines
4) BC Cancer Agency Clinical Practice Guidelines